Medical experts provide a comprehensive approach to proactively treathigh levels of LDL, highlighting lesser-known therapies and trials that could benefit the field and mitigatehyperchlolesteromia.
EP. 1: Overview of Low-Density Lipoprotein Cholesterol Management
May 1st 2024Erin Michos, MD, delivers a comprehensive review of lipid management and its influence on cardiovascular disease, emphasizing recent studies that underscore the need for improved treatment strategies for high-risk patients.
EP. 2: Stricter LDL-C Targets: Explaining Goalpost Changes to Patients
May 1st 2024Key opinion leaders in cardiology share insights on reducing LDL cholesterol to manage cardiovascular disease risk, educating patients not reaching goals, and implementing real-world clinical strategies for maintaining lower LDL levels.
EP. 3: Ongoing Lp(a) Trials and Clinical Approaches to Treatment
May 8th 2024Panelists discuss ongoing clinical trials aimed at lowering Lipoprotein(a) levels, emphasizing the importance of proactive patient testing, and referring to new guidelines recommending that everyone be tested once in their lifetime.
EP. 4: Innovations in Small Interfering RNA (siRNA) Therapy
May 8th 2024Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.
EP. 5: Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data
May 15th 2024Michael Blaha, MD, discusses the efficacy and safety of novel targeted therapies for lowering LDL cholesterol and emphasizes the importance of long-term data in building patient confidence in this new treatment option.
EP. 6: Evaluating Safety of Novel LDL Management Mechanism
May 15th 2024Deepak Bhatt, MD, MPH, MBA, reviews the efficacy and safety data of inclisiran, highlighting its long-term effects and noting that injection site reactions are among the most prominent adverse reactions associated with this medication.